Rani Therapeutics Reports Third Quarter 2023 Financial
- Cash runway extended into 2025 - - Announced strategic program prioritization, expansion of manufacturing and plans to streamline business operations - ...
United States Talat Imran Adalimumab Biosimilar Ustekinumab Biosimilar Rani Therapeutics Holdings Inc Meeting Of The American Society For Bone
Source: globenewswire.com